2 recruiting, 1 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Hemab ApS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency Sutacimig - Congenital Factor VII Deficiency | Phase 2 | Recruiting | Hemab ApS | 18 | 2026-03-11 | 2026-07-22 |
| A Study Assessing HMB-002 in Participants With Von Willebrand Disease HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) - Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1 | Phase 1 / Phase 2 | Recruiting | Hemab ApS | 108 | 2025-02-06 | 2026-06-30 |
| A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia HMB-001 - Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Active not recruiting | Hemab ApS | 57 | 2022-12-13 | 2026-09-25 |
Factor VII Deficiency (1) · Thrombasthenia (1) · von Willebrand Disease, Type 3 (1) · von Willebrand Diseases (1)
United Kingdom (3) · United States (2) · Australia (1) · Belgium (1) · France (1) · Italy (1) · Netherlands (1)